당뇨병성 신증의 최신 치료 -새로운 약제를 중심으로-

키워드

참고문헌 (36)

1. 대한신장학회, "우리나라 신대체 요법의 현황", 대한신장학회지, 26, pp.459~481 (2007)
2. Writing Team for the Diabetes Control and Complications Trial, "Epidemiology of Diabetes Interventions and Complications Research Group", Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Intervention and Complication (EDIC) study, 2003, pp.290, 2159~2167
3. Stratton IM, "Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study", BMJ, 321, pp.405~412 (2000)
4. American Diabetes Association, "Standards of medical care in diabetes: 2008", Diabetes Care, 31(1), pp.S12~S54 (2008)
5. Gaede P, "Effect of a multifactorial intervention on mortality in type 2 diabetes", N Engl J Med, 358, pp.580~591 (2008)
6. Schjoedt KJ, "Aldosterone escape during blockade of the renin-angiotensin- aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate", Diabetologia, 47, pp.1936~1939 (2004)
7. Bomback AS, "Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systemic review", Am J Kidney Dis, 51, pp.199~211 (2008)
8. Segall L, "Direct renin inhibitors: the dawn of a new era, or just a variation on a theme?", Nephrol Dial Transplant, 22, pp.2435~2439 (2007)
9. Dieterle W, "Pharmacolkinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects", J Clin Pharmacol, 44, pp.59~66 (2004)
10. Tabrizchi R, "Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension", Curr Opin Investig Drugs, 9, pp.301~309 (2008)
11. Oldfield MD, "Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)", J Clin Invest, 108, pp.1853~1863 (2001)
12. Soulis-Liparota T, "The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat", Diabetologia, 38, pp.387~394 (1995)
13. Tsuchida K, "Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195", Diabetologia, 42, pp.579~588 (1999)
14. Forbes JM, "Renoprotective effectsof a novel inhibitor of advanced glycation", Diabetologia, 44, pp.108~114 (2001)
15. Wendt TM, "RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy", Am J Pathol, 162, pp.1123~1137 (2003)
16. Zheng F, "Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db", db mice, 2006, pp.70, 507~514
17. Cha DR, "Peroxisome proliferator activated receptor alpha", gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db, Diabetes, pp.2007, 56[DOI]
18. Park CW, "PPAR-alpha agonist fenofibrate improves diabetic nephropathy in db", db mice, 2006, pp.69, 1511~1517
19. Keech A, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial", Lancet, 366, pp.1849~1861 (2005)
20. Koya D, "Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta extracellular matrix components and prostanoids in the glomeruli of diabetic rat", J Clin Invest, 100, pp.115~126 (1997)
21. Meier M, "Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model", Diabetes, 56, pp.346~354 (2007)
22. He Z, "Can protein kinase C beta-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients?", Diabetes Care, 28, pp.2803~2805 (2005)
23. Szabo C, "Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb", db mice, 2006, pp.55, 3004~3012
24. Nagai K, "Gas6 induces Akt", mTOR-mediated mesangial hypertrophy in diabetic nephropathy, 2005, pp.68, 552~561
25. Russo LM, "Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor", Diabetes, 56, pp.380~388 (2007)
26. Sugaru E, "Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy", Am J Nephrol, 26, pp.50~58 (2006)
27. Shibuya K, "N-acetyl- seryl-aspartyl-lysyl-proline prevents renal insuffi ciency and mesangial matrix expansion in diabetic db", db mice, 2005, pp.54, 838~845
29. Lassila M, "Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products", J Am SocNephrol, 15, pp.2125~2138 (2004)
30. Sung SH, "Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice", J Am Soc Nephrol, 17, pp.3093~3104 (2006)
31. Gambaro G, "sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial", J Am Soc Nephrol, 13, pp.1615~1625 (2002)
32. Zhang Z, "Renoprotective role of the vitamin D receptor in diabetic nephropathy", Kidney Int, 73, pp.163~171 (2008)
33. Tikellis C, "Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy", Hypertension, 41, pp.392~397 (2003)
34. Kolavennu V, "Targeting of RhoA", ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control, 2008, pp.57, 714~723
35. Lee HB, "Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy", Kidney Int, (106), pp.S61~S66 (2007)
36. Goh SY, "Agents in development for the treatment of diabetic nephropathy", Expert Opin Emerg Drugs, 13, pp.447~463 (2008)

관련 논문AI추천